Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The need for cytoprotection

R M Bukowski1

  • 1Cleveland Clinic Foundation, Department of Hematology/Oncology, Cleveland Clinic Cancer Center, Ohio 44195-5237, USA.

European Journal of Cancer (Oxford, England : 1990)
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.

British journal of cancer·2014
Same author

A phase I study of sunitinib plus bevacizumab in advanced solid tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2009
Same author

Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.

Investigational new drugs·2008
Same author

Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same author

Downregulation of topoisomerase IIbeta in myeloid leukemia cell lines leads to activation of apoptosis following all-trans retinoic acid-induced differentiation/growth arrest.

Leukemia·2006
Same author

Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2006
Same journal

Early-onset colorectal cancer across Europe: Burden, mechanisms, and health-system implications.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinical urgency of incidental findings in the first year of the 4-IN-THE-LUNG-RUN lung cancer screening program.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Mapping the anatomical landscape of colorectal tumours: Location-specific efficacy of anti-epidermal growth factor receptor antibodies: Pooled analysis of randomised trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Left behind but not left alone: Excluded cell populations in the non-small cell lung cancer stroma predict superior long-term overall survival.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Survival outcomes of adjuvant therapy in resected stage III melanoma: Results from a real-life cohort study (TAMARIS).

European journal of cancer (Oxford, England : 1990)·2026
See all related articles

Chemotherapy causes significant toxicity, limiting treatment doses. Amifostine (WR-2721) shows promise as a cytoprotective agent, selectively protecting normal tissues from chemotherapy side effects.

Area of Science:

  • Oncology
  • Pharmacology
  • Toxicology

Background:

  • Chemotherapy is associated with significant dose-limiting toxicities affecting multiple organ systems.
  • Acute and chronic side effects of chemotherapy can lead to adverse outcomes.
  • Cytoprotection strategies aim to selectively protect normal tissues during cancer treatment.

Purpose of the Study:

  • To investigate the potential of cytoprotective agents in mitigating chemotherapy-induced toxicity.
  • To evaluate systemic approaches for selective normal tissue protection.

Main Methods:

  • Review of preclinical and clinical models investigating cytoprotective compounds.
  • Analysis of systemic agents including sodium thiosulphate, diethyldithiocarbamate, and amifostine.

Related Experiment Videos

Main Results:

  • Amifostine (WR-2721), an organic thiophosphate, has demonstrated the most promising results.
  • Selective protection of normal tissues is a key finding.

Conclusions:

  • Amifostine (Ethyol, WR-2721) is a highly promising cytoprotective agent for managing chemotherapy toxicity.
  • Further investigation in preclinical and clinical settings supports its therapeutic potential.